| VSCIX | VSCPX | VSCIX / VSCPX | |
| Total Expense Ratio | 0.03 | 0.02 | 150% |
| Annual Report Gross Expense Ratio | 0.03 | 0.02 | 150% |
| Fund Existence | 29 years | 16 years | - |
| Gain YTD | 14.591 | 14.596 | 100% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 5000000 | 100000000 | 5% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 189B | 189B | 100% |
| Annual Yield % from dividends | 1.23 | 1.24 | 99% |
| Returns for 1 year | 22.58 | 22.59 | 100% |
| Returns for 3 years | 43.44 | 43.45 | 100% |
| Returns for 5 years | 35.13 | 35.15 | 100% |
| Returns for 10 years | 156.07 | 156.12 | 100% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GSPQX | 20.02 | 0.12 | +0.60% |
| Goldman Sachs US Eq Div and Premium C | |||
| CAVAX | 18.71 | 0.04 | +0.21% |
| SEI Catholic Values Equity F (SCVT) | |||
| GSIYX | 24.29 | N/A | N/A |
| Goldman Sachs GQG Ptnrs Intl Opps R6 | |||
| PIEQX | 22.30 | -0.17 | -0.76% |
| T. Rowe Price International Eq Index | |||
| RYOIX | 86.56 | -2.00 | -2.26% |
| Rydex Biotechnology Inv | |||